このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

LAmbre™ II 左心耳閉鎖デバイスおよび閉鎖デバイス送達システム(非弁膜症性心房細動患者用) (LAmbre2)

2026年9月15日 更新者:Dr So Chak Yu kent、Prince of Wales Hospital, Shatin, Hong Kong

非弁膜症性心房細動患者を対象としたLAmbre™II左心耳閉鎖栓および閉鎖栓送達システムの初回人体(FIM)試験

Worldwide, atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. The prevalence of AF gradually increases with age; its prevalence is 0.5% ~ 0.8% among 45 ~ 59 year-olds, 1.8% ~ 5.9% among 60 ~ 69 year-olds, and 6.7% ~17.9% among > 79 year-olds. Thromboembolic complications are the leading cause of death and disability in patients with AF, with ischemic stroke being the most common complication. AF significantly increases the risk of stroke by 3- to 5-fold due to thrombosis caused by abnormal atrial beat. The overall risk of ischemic stroke in patients with AF is 20% ~ 30%, and strokes due to atrial fibrillation account for 20% of all strokes.

In the current 2023 ACC/AHA/ACCP/HRS Guideline, percutaneous LAAC has been classified as a Class 2a indication for stroke prevention in patients with AF, a moderate to high risk of stroke, and a contraindication to long-term oral anticoagulation due to a nonreversible cause. However, the implantation procedure does have adverse effects which include serious pericardial effusion, procedure-related ischemic stroke, and device embolization. Due to the anatomical diversity of the LAA, certain patients are not candidates for this device.

The LAmbre™ Left Atrial Appendage Closure System, manufactured by Lifetech Scientific (Shenzhen) Co.Ltd., is the first generation of LAmbre LAAO device which is CE-marked and is current approved in Hong Kong Hospital Authority for regular clinical use. It consists of a LAA Occluder and a Delivery System and is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage in patients who have nonvalvular atrial fibrillation.

This self-expanding LAA Occluder consists of an umbrella and a cover connected by a central waist. Although the first generation of LAmbre LAAO device is associated with high implantation success rate of 99.7% and a relatively low major procedure-related complication rate of 2.9%, to better match the challenging anatomy of the LAA and to further improve procedural safety, the first generation of LAmbre LAAO device has been upgraded.

The LAmbre™ II Left Atrial Appendage Occluder, designed to prevent thrombus embolization and reduce the risk of bleeding events in patients with non-valvular atrial fibrillation, is being evaluated in a prospective, single-center, single-arm First In Man (FIM) study. The study, conducted at the Prince of Wales Hospital, Chinese University of Hong Kong, aims to assess the preliminary safety and feasibility of the device and its Occluder Delivery System in 10 subjects who are at increased risk for stroke and systemic embolism, either due to their anticoagulation therapy eligibility or contraindications.

The enrollment period is expected to take approximately 6 months and subjects will have follow-up before discharge and at 30 days, 3M, 6M, 12M months post-operation. The total study duration is expected to be approximately 19 months.

調査の概要

状態

積極的、募集していない

研究の種類

介入

入学 (推定)

10

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Shatin、香港
        • The Chinese University of Hong Kong

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • The patient age ≥18 years;
  • The patient has documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation;
  • The patient has a CHA2DS2-VASc score of ≥ 2 in men and CHA2DS2-VASc score of ≥ 3 in women;
  • The patient is recommended for oral anticoagulation therapy, but there is an appropriate rationale for seeking a non-pharmacologic alternative to oral anticoagulation;
  • The patient is deemed suitable for LAA closure by the site investigator and a clinician not a part of the procedural team in the shared decision-making process, and this determination has been documented in the patient's medical record;
  • The patient is willing and able to comply with the required medication post-procedure and follow-up evaluations;
  • The patient (or his or her legally authorized representative) has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

Exclusion Criteria:

  • 1. Pregnant or nursing patients and those who plan pregnancy during the study period. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to the index procedure;
  • Patients with atrial fibrillation that is defined by a single occurrence, or that is transient or reversible (e.g., secondary to CABG, an interventional procedure, pneumonia, or hyperthyroidism);
  • Patients who require long-term anticoagulation for a condition other than atrial fibrillation;
  • Bleeding diathesis or coagulopathy;
  • Patients with rheumatic mitral valve disease, known severe mitral stenosis requiring surgical or percutaneous valve replacement, or existing mechanical valve prosthesis;
  • Active infection with bacteremia;
  • Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, any device material or component (nickel titanium, PET, polypropylene), and/or contrast sensitivity;
  • Prior atrial septal defect (ASD) or patient foramen ovale (PFO) surgical repair or implantation of closure device;
  • Left atrial appendage is obliterated and surgical ligated;
  • Underwent any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to the procedure or planned to have the interventional or surgical procedure within 60 days after implant procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, cataract surgery, etc.);
  • Recent (within 90 days prior to procedure) stroke, transient ischemic attack, or myocardial infarction;
  • New York Heart Association Class IV;
  • Patients with severe renal failure (estimated glomerular filtration rate<30 ml/min/1.73m2);
  • Known asymptomatic carotid artery disease with>70% diameter stenosis OR symptomatic carotid disease (>50% diameter stenosis with ipsilateral stroke or TIA). Subjects with prior carotid endarterectomy or carotid stent placement may be enrolled, provided that known diameter stenosis is <50%;
  • Life expectancy is less than 1 year;
  • Current participation in another investigational drug or device study.

Echocardiographic Exclusion Criteria:

  • Left atrial appendage anatomy cannot accommodate the LAmbre II LAA Occluder per manufacturer IFU;
  • LVEF <30%;
  • Intracardiac thrombus or dense spontaneous echo contrast, as visualized by TEE prior to implant;
  • Presence of a high-risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion >15 mm or length >15 mm) or large shunt (early, within 3 beats and/or substantial passage of 20 bubbles);
  • Existing circumferential pericardial effusion >5 mm;
  • Moderate or severe mitral valve stenosis (mitral valve area <1.5 cm2);
  • Complex atheroma with mobile plaque of the descending aorta and/or aortic arch;
  • Presence of a cardiac tumor

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:介入

The LAmbre™ II Left Atrial Appendage Occluder, designed to prevent thrombus embolization and reduce the risk of bleeding events in patients with non-valvular atrial fibrillation

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
LAA closure success rate
時間枠:3 months post-procedure

complete LAA closure or peri-device residual leak ≤3 mm measured by TEE at 3 months post-procedure

3 months post-procedure
Procedural complication rate
時間枠:peri-procedure

Rate of complication rate peri-procedure

peri-procedure

二次結果の測定

結果測定
メジャーの説明
時間枠
Rate of death
時間枠:Perioperative

Rate of death at discharge

Perioperative
Rate of stroke
時間枠:Perioperative

Rate of stroke at discharge

Perioperative
Rate of stroke
時間枠:At 30 days post-OP

Rate of stroke at 30 days post-OP

At 30 days post-OP
Rate of stroke
時間枠:At 6 months post-OP

Rate of stroke at 6 months post-OP

At 6 months post-OP
Rate of stroke
時間枠:At 12 months post-OP

Rate of stroke at 12 months post-OP

At 12 months post-OP
Rate of systemic embolism
時間枠:Perioperative

Rate of systemic embolism at discharge

Perioperative
Rate of systemic embolism
時間枠:At 30 days post-OP

Rate of systemic embolism at 30 days post-OP

At 30 days post-OP
Rate of systemic embolism
時間枠:At 3 months post-OP

Rate of systemic embolism at 3 months post-OP

At 3 months post-OP
Rate of systemic embolism
時間枠:At 6 months post-OP

Rate of systemic embolism at 6 months post-OP

At 6 months post-OP
Rate of systemic embolism
時間枠:At 12 months post-OP

Rate of systemic embolism at 12 months post-OP

At 12 months post-OP
Rate of pericardial effusion with tamponade
時間枠:Perioperative

Rate of pericardial effusion with tamponade at discharge

Perioperative
Rate of pericardial effusion with tamponade
時間枠:At 30 days post-OP

Rate of pericardial effusion with tamponade at 30 days post-OP

At 30 days post-OP
Rate of pericardial effusion with tamponade
時間枠:At 3 months post-OP

Rate of pericardial effusion with tamponade at 3 months post-OP

At 3 months post-OP
Rate of pericardial effusion with tamponade
時間枠:At 6 months post-OP

Rate of pericardial effusion with tamponade at 6 months post-OP

At 6 months post-OP
Rate of pericardial effusion with tamponade
時間枠:At 12 months post-OP

Rate of pericardial effusion with tamponade at 12 months post-OP

At 12 months post-OP
Rate of pericardial effusion requiring drainage
時間枠:Perioperative

Rate of pericardial effusion requiring drainage at discharge

Perioperative
Rate of pericardial effusion requiring drainage
時間枠:At 30 days post-OP

Rate of pericardial effusion requiring drainage at 30 days post-OP

At 30 days post-OP
Rate of pericardial effusion requiring drainage
時間枠:At 3 months post-OP

Rate of pericardial effusion requiring drainage at 3 months post-OP

At 3 months post-OP
Rate of pericardial effusion requiring drainage
時間枠:At 6 months post-OP

Rate of pericardial effusion requiring drainage at 6 months post-OP

At 6 months post-OP
Rate of pericardial effusion requiring drainage
時間枠:At 12 months post-OP

Rate of pericardial effusion requiring drainage at 12 months post-OP

At 12 months post-OP
Rate of device embolization
時間枠:Perioperative

Rate of device embolization at discharge

Perioperative
Rate of device embolization
時間枠:At 30 days post-OP

Rate of device embolization at discharge at 30 days post-OP

At 30 days post-OP
Rate of device embolization
時間枠:At 3 months post-OP

Rate of device embolization at 3 months post-OP

At 3 months post-OP
Rate of death
時間枠:At 30 days

Rate of death at 30 days

At 30 days
Rate of death
時間枠:At 3 months post-OP

Rate of death at 3 months post-OP

At 3 months post-OP
Rate of death
時間枠:At 6 months post-OP

Rate of death at 6 months post-OP

At 6 months post-OP
Rate of death
時間枠:At 12 months post-OP

Rate of death at 12 months post-OP

At 12 months post-OP
Rate of device embolization
時間枠:At 6 months post-OP

Rate of device embolization at 6 months post-OP

At 6 months post-OP
Rate of device embolization
時間枠:At 12 months post-OP

Rate of device embolization at 12 months post-OP

At 12 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
時間枠:Perioperative

Rate of major bleeding (BARC defined 3 to 5) at discharge

Perioperative
Rate of major bleeding (BARC defined 3 to 5)
時間枠:At 30 days post-OP

Rate of major bleeding (BARC defined 3 to 5) at 30 days post-OP

At 30 days post-OP
Rate of major bleeding (BARC defined 3 to 5)
時間枠:At 3 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 3 months post-OP

At 3 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
時間枠:At 6 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 6 months post-OP

At 6 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
時間枠:At 12 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 12 months post-OP

At 12 months post-OP
Closure success assessed by TEE or cardiac computed tomography
時間枠:At 30 days post-procedure

Closure success assessed by TEE or cardiac computed tomography at 30 days post-procedure

At 30 days post-procedure
Closure success assessed by TEE or cardiac computed tomography
時間枠:At 6 months post-procedure

Closure success assessed by TEE or cardiac computed tomography at 6 months post-procedure

At 6 months post-procedure
Closure success assessed by TEE or cardiac computed tomography
時間枠:At 12 months post-procedure

Closure success assessed by TEE or cardiac computed tomography at 12 months post-procedure

At 12 months post-procedure
Rate of minor bleeding (BARC type 2)
時間枠:At discharge, 30 days and 3, 6, 12 months post-procedure

Rate of minor bleeding (BARC type 2) at discharge

At discharge, 30 days and 3, 6, 12 months post-procedure
Rate of minor bleeding (BARC type 2)
時間枠:At 30 days post-procedure

Rate of minor bleeding (BARC type 2) at 30 days post-procedure

At 30 days post-procedure
Rate of minor bleeding (BARC type 2)
時間枠:At 3 months post-procedure

Rate of minor bleeding (BARC type 2) at 3 months post-procedure

At 3 months post-procedure
Rate of minor bleeding (BARC type 2)
時間枠:At 6 months post-procedure

Rate of minor bleeding (BARC type 2) at 6 months post-procedure

At 6 months post-procedure
Rate of minor bleeding (BARC type 2)
時間枠:At 12 months post-procedure

Rate of minor bleeding (BARC type 2) at 12 months post-procedure

At 12 months post-procedure
Rate of cardiovascular death
時間枠:Perioperative

Rate of cardiovascular death at discharge

Perioperative
Rate of cardiovascular death
時間枠:At 30 days post-procedure

Rate of cardiovascular death at 30 days post-procedure.

At 30 days post-procedure
Rate of cardiovascular death
時間枠:At 3 months post-procedure

Rate of cardiovascular death at 3 months post-procedure.

At 3 months post-procedure
Rate of cardiovascular death
時間枠:At 6 months post-procedure

Rate of cardiovascular death at 6 months post-procedure.

At 6 months post-procedure
Rate of cardiovascular death
時間枠:At 12 months post-procedure

Rate of cardiovascular death at 12 months post-procedure.

At 12 months post-procedure
Rate of ischemic stroke
時間枠:Perioperative

Rate of ischemic stroke at discharge

Perioperative
Rate of ischemic stroke
時間枠:At 30 days post-procedure

Rate of ischemic stroke at 30 days post-procedure

At 30 days post-procedure
Rate of ischemic stroke
時間枠:At 3 months post-procedure

Rate of ischemic stroke at 3 months post-procedure

At 3 months post-procedure
Rate of ischemic stroke
時間枠:At 6 months post-procedure

Rate of ischemic stroke at 6 months post-procedure

At 6 months post-procedure
Rate of ischemic stroke
時間枠:At 12 months post-procedure

Rate of ischemic stroke at 12 months post-procedure

At 12 months post-procedure
Rate of hemorrhagic stroke
時間枠:Perioperative

Rate of hemorrhagic stroke at discharge

Perioperative
Rate of hemorrhagic stroke
時間枠:At 30 days post-procedure

Rate of hemorrhagic stroke at 30 days post-procedure

At 30 days post-procedure
Rate of hemorrhagic stroke
時間枠:At 3 months post-procedure

Rate of hemorrhagic stroke at 3 months post-procedure

At 3 months post-procedure
Rate of hemorrhagic stroke
時間枠:At 6 months post-procedure

Rate of hemorrhagic stroke at 6 months post-procedure

At 6 months post-procedure
Rate of hemorrhagic stroke
時間枠:At 12 months post-procedure

Rate of hemorrhagic stroke at 12 months post-procedure

At 12 months post-procedure
Rate of systemic embolization
時間枠:Perioperative

Rate of systemic embolization at discharge

Perioperative
Rate of systemic embolization
時間枠:At 30 days post-procedure

Rate of systemic embolization at 30 days post-procedure

At 30 days post-procedure
Rate of systemic embolization
時間枠:At 3 months post-procedure

Rate of systemic embolization at 3 months post-procedure

At 3 months post-procedure
Rate of systemic embolization
時間枠:At 6 months post-procedure

Rate of systemic embolization at 6 months post-procedure

At 6 months post-procedure
Rate of systemic embolization
時間枠:At 12 months post-procedure

Rate of systemic embolization at 12 months post-procedure

At 12 months post-procedure
Procedural Technical success rate
時間枠:During procedure

Procedural Technical success rate, defined as successful delivery and release of study device with acceptable device position and stability, and closure success;

During procedure
Procedural success rate
時間枠:Peri-procedure

Procedural success rate, defined as technical success without major peri-procedural complications

Peri-procedure
Rate of Device-related thrombosis
時間枠:At 30 days post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 30 days post-procedure

At 30 days post-procedure
Rate of Device-related thrombosis
時間枠:At 3 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 3 months post-procedure

At 3 months post-procedure
Rate of Device-related thrombosis
時間枠:At 6 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 6 months post-procedure

At 6 months post-procedure
Rate of Device-related thrombosis
時間枠:At 12 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 12 months post-procedure

At 12 months post-procedure

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年3月5日

一次修了 (推定)

2027年11月1日

研究の完了 (推定)

2028年5月1日

試験登録日

最初に提出

2026年2月25日

QC基準を満たした最初の提出物

2026年3月2日

最初の投稿 (実際)

2026年3月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月18日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2025.451

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する